Mineralys Therapeutics
Stock Forecast, Prediction & Price Target

Mineralys Therapeutics Financial Estimates

Mineralys Therapeutics Revenue Estimates

Mineralys Therapeutics EBITDA Estimates

Mineralys Therapeutics Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$0
 
N/A
$0
 
0%
$0
 
0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $78.07M
Low: $78.07M
High: $78.07M
avg. 0%
Avg: $206.89M
Low: $206.89M
High: $206.89M
avg. 165.00%
Net Income
 
% change YoY
$-19.40M
 
N/A
$-29.79M
 
-53.53%
$-71.89M
 
-141.27%
Avg: $-173.20M
Low: $-133.53M
High: $-97.34M
avg. -140.89%
Avg: $-192.04M
Low: $-157.41M
High: $-92.28M
avg. -10.87%
Avg: $-142.46M
Low: $-142.46M
High: $-142.46M
avg. 25.81%
Avg: $-90.22M
Low: $-90.22M
High: $-90.22M
avg. 36.66%
EBITDA
 
% change YoY
$-18.72M
 
N/A
$-31.47M
 
-68.12%
$-84.65M
 
-168.93%
Avg: $0
Low: $0
High: $0
avg. 100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
EPS
 
% change YoY
-$0.5
 
N/A
-$0.73
 
-46%
-$1.99
 
-172.60%
Avg: -$3.21
Low: -$3.69
High: -$2.69
avg. -61.05%
Avg: -$3.39
Low: -$4.35
High: -$2.55
avg. -5.66%
Avg: -$3.94
Low: -$3.94
High: -$3.94
avg. -16.24%
Avg: -$2.49
Low: -$2.49
High: -$2.49
avg. 36.66%
Operating Expenses
 
% change YoY
$18.72M
 
N/A
$31.47M
 
68.11%
$84.65M
 
168.93%
Avg: $0
Low: $0
High: $0
avg. -100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%

FAQ

What is Mineralys Therapeutics stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of -22.32% in 2025-2028.

We have gathered data from 3 analysts. Their low estimate is -133.53M, average is -173.20M and high is -97.34M.

What is Mineralys Therapeutics stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 41.25% in 2025-2028.

We have gathered data from 3 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.

What is Mineralys Therapeutics stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of -11.57% in 2025-2028.

We have gathered data from 3 analysts. Their low earnings per share estimate is -$3.69, average is -$3.21 and high is $-2.69.

What is the best performing analyst?

In the last twelve months analysts have been covering Mineralys Therapeutics stock. The most successful analyst is Richard Law.